TOURMALINE BIO INC. - COMMON STOCK

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

16 May 2024 04:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

13 May 2024 04:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

19 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

27 Feb 2024 04:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

29 Jan 2024 13:01:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

25 Jan 2024 04:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Proposed Public Offering of Common Stock

24 Jan 2024 13:05:48 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

08 Jan 2024 04:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio added to the NASDAQ Biotechnology Index

15 Dec 2023 13:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

14 Dec 2023 04:30:00 By Nasdaq GlobeNewswire